Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 54 clinical trials
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems.

  • 254 views
  • 30 Apr, 2022
  • 67 locations
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant

The haematological neoplasia relapse is the cause of higher mortality after allogeneic stem cell transplantation (HSCT). When transplantation fails the most common therapeutic strategy is to increase the antitumor activity of the donor's immune system through the infusion of donor Lymphocytes (DLI). The use of DLI may limit the relapse, …

  • 0 views
  • 01 Jan, 2022
  • 1 location
SYMPHONY-1: A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker enrichment design featuring early futility stopping and sample-size re-estimation with safety run-in designed to evaluate the efficacy and safety of tazemetostat in combination with lenalidomide and rituximab (R2) in subjects with relapsed or refractory (R/R) follicular lymphoma (FL), who have completed …

  • 2 views
  • 29 Oct, 2022
  • 119 locations
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (MANIFEST-2)

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

  • 1 views
  • 23 Oct, 2022
  • 138 locations
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy (PEACH)

A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendritic Cells (DCs) (TTRNA-DCs), Tumor-specific ex vivo expanded autologous lymphocyte …

neutrophil count
cancer
colony stimulating factor
bone marrow procedure
filgrastim
  • 0 views
  • 14 May, 2022
  • 2 locations
Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

The goal of this study is to determine the safety and efficacy of fresh metabolically active allogeneic umbilical cord-derived mesenchymal stromal cells (UC-MSCs) for the treatment of new-onset type 1 diabetes (T1D) and to understand the mechanisms of protection. If proven effective, such a strategy can be used as a …

diabetes
autoimmune disease
  • 49 views
  • 26 Apr, 2022
  • 1 location
Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (ACTION)

It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells are not stimulated enough to …

malignant glioma
tumor cells
MRI
corticosteroids
neutrophil count
  • 13 views
  • 07 Oct, 2022
  • 3 locations
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

Single center Phase 1 dose escalation trial of the combination of standard-of-care blinatumomab plus Haplo-Mismatched Cellular Therapy (HMCT). HMCT refers to the infusion of donor peripheral

cytopenias
blinatumomab
stem cell transplantation
cellular therapy
gilbert's syndrome
  • 0 views
  • 06 Jun, 2022
  • 1 location
Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial (CuRe)

Spina bifida, or myelomeningocele (MMC), is a disorder where the lower part of the spinal cord of the fetus is exposed, meaning there is no bone or skin covering it. This is dangerous because the spinal cord contains cells which control one's ability to move their legs and walk, and …

  • 0 views
  • 07 Oct, 2022
  • 1 location
PRGN-3006 Adoptive Cellular Therapy for Relapsed or Refractory AML or Higher Risk MDS

This is a first-in-human dose escalation/dose expansion study to evaluate the safety and identify the best dose (or recommended Phase 2 dose) of modified immune cells, PRGN-3006 (autologous chimeric antigen receptor (CAR) T cells), in adult patients with relapsed or recurred acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS). Autologous …

hemolysis
refractory acute myeloid leukemia (aml)
blood transfusion
direct bilirubin
leukemia
  • 9 views
  • 04 Oct, 2022
  • 1 location